Accueil>>Signaling Pathways>> Antibody-drug Conjugate/ADC Related>> ADC Linker>>Mal-amido-PEG10-C2-NHS ester

Mal-amido-PEG10-C2-NHS ester

Catalog No.GC38563

L'ester mal-amido-PEG10-C2-NHS est un lieur ADC non clavetable contenant un groupe maléimide et un ester NHS. L'ester NHS peut être utilisé pour marquer les amines primaires (-NH2) des protéines, des oligonucléotides modifiés par des amines et d'autres molécules contenant des amines.

Products are for research use only. Not for human use. We do not sell to patients.

Mal-amido-PEG10-C2-NHS ester Chemical Structure

Cas No.: 1137109-22-8

Taille Prix Stock Qté
50mg
214,00 $US
En stock
100mg
342,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Mal-amido-PEG10-C2-NHS ester is a nonclaevable ADC linker containing a maleimide group and an NHS ester. The NHS ester can be used to label the primary amines (-NH2) of proteins, amine-modified oligonucleotides, and other amine-containing molecules[1][2].

[1]. Hansen AM, et al. Microwave-assisted solid-phase synthesis of antisense acpP peptide nucleic acid-peptide conjugates active against colistin- and tigecycline-resistant E. coli and K. pneumoniae. Eur J Med Chem. 2019 Apr 15;168:134-145. [2]. Zhang ge, et al. Preparation and application of FAPalpha activated polypeptide magnetic nanosphere compound used for diagnosis of tumors. CN105524141A

Avis

Review for Mal-amido-PEG10-C2-NHS ester

Average Rating: 5 ★★★★★ (Based on Reviews and 27 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Mal-amido-PEG10-C2-NHS ester

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.